In chronic lymphocytic leukaemia (CLL), they are associated with a poor response to chemotherapy and detection of TP53 mutation and 17p deletion is used to guide therapeutic decisions [39]. Here, TP53 is linked to B-cell chronic lymphocytic leukemia.